A delayed clinical trial actually boosted Bristol Myers Squibb’s stock. Here’s why.  

by | Dec 3, 2025 | Stock Market

Bristol Myers’ stock rallied Wednesday as investors maintained high hopes for Cobenfy as an Alzheimer’s treatment, even though the outcome of a late-stage trial has been delayed.

Article Attribution | Read More at Article Source